Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PSORIASIS IL17

Financiado

Cerrado

Investigating the role of dysregulated Interleukin 17 signalling in the pathogen...

Investigating the role of dysregulated Interleukin 17 signalling in the pathogenesis of psoriasis Psoriasis is the most prevalent autoimmune disease, affecting approximately 125 million people worldwide. In Ireland alone it costs the health care system approximately 30 million euro yearly. Psoriasis is characterised by inflame... ver más

31/08/2016

UZH

208K€

Presupuesto del proyecto: 208K€

Líder del proyecto

University of Zurich No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-08-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UZH

207.93K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PSORIASIS-TREAT Directed Evolution of Soluble IL 17A Receptor for Psoriasis... 168K€ Cerrado

SAF2013-43833-R ESTUDIO DE LAS CASCADAS DE SEÑALIZACION DE LA CITOQUINA PRO-... 145K€ Cerrado

SAF2016-78180-R ESTUDIO DE LOS MECANISMOS MOLECULARES REGULADOS POR LA INTER... Cerrado

DocTIS DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMIDS USING S... 6M€ Cerrado

DESARROLLO PRECLÍNICO NO REGULATORIO DEL PÉPT... DESARROLLO PRECLÍNICO NO REGULATORIO DEL PÉPTIDO MTADV PEMT... 551K€ Cerrado

CSI-Fun Chronic Systemic Inflammation Functional organ cross talk i... 2M€ Cerrado

Líder del proyecto

University of Zurich No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 208K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Psoriasis is the most prevalent autoimmune disease, affecting approximately 125 million people worldwide. In Ireland alone it costs the health care system approximately 30 million euro yearly. Psoriasis is characterised by inflamed scaly red psoriatic plaques on the epidermis of sufferers and 20% of patients develop severe psoriasis, which is associated with an increased risk of cardiovascular disease and metabolic syndrome. Psoriasis can also be detrimental to a patient's psychological well-being. As there is no cure a psoriasis patient has a life-long struggle with managing the disease. Anti-Interleukin-17 (IL-17) biologics that target IL-17A and IL-17 receptor A have proved successful in clinical trials in treating psoriasis, however, how IL-17 cytokines mediate the inflammatory effects in psoriasis pathogenesis remains incompletely understood. These biologic therapies, though highly efficacious, will remain unavailable to the majority of psoriasis patients due to their expense. New research findings suggest that there are more suitable therapeutic targets amongst the IL-17 cytokine and receptor families, which may not be as critical to the host’s response to infection, emphasising a need for new therapeutic strategies. We propose to characterise the physiological role of IL-17 receptor D in psoriasis pathogenesis and present preliminary data to suggest that this role is protective. We also propose, with supporting data, that IL-17C may contribute to psoriasis pathogenesis by activating the IL-1 inflammasome and IL-17RD may regulate this. We propose to use a psoriasiform disease model in Il-17rd-deficient mice to characterise its function and samples from psoriasis patients to isolate primary keratinocytes to dissect IL-17C signalling pathways. Determining the roles of IL-17C and IL-17RD will aid in finally treating psoriasis effectively and would also aid in comprehending the role of dysregulated IL-17 signalling in other chronic inflammatory diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores